Contoured prism lenses may resolve symptoms such as neck, shoulder, and head pain.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

Jason Romero, a legally blind ultra-runner, will be giving the keynote address at the 2023 Vision Expo East meeting March 16-19 in New York City.

A look back on what's happened in optometry during the week of February 11-February 16.

The eye care community is moving toward a more disruption-resistant system of care, from wearable tech to VEGF-eluting implants.

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

The next-generation compound of atropine does not contain preservatives or boric acid and can be stored at room temperature for up to 180 days.

The Biosciences group of the Centre for Ocular Research and Education (CORE) determined protein deposits on rigid gas permeable contact lens via radioactive counts by using a radiolabeled lysozyme in an artificial tear solution.

Vote in our most recent poll!

Patrick Mooney, CEO of SpyGlass Pharma, sits down to discuss the 6-month first-in-human clinical trial data of their drug delivery platform with bimatoprost, which is implanted during routine cataract surgery.

Medical and surgical technological advances show promise for future glaucoma management.

Phentolamine ophthalmic solution 0.75%, or Nyxol, receives a PDUFA date of September 28, 2023, for the indication of reversal of pharmacologically induced mydrasis.

Advances in drug creation would reduce cost burden of treatment for patients.

See the results from our recent poll!

A look back on what's happened in optometry during the week of February 4-February 9.

Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.

Hear from Robert Maloney, MD, about what to expect—and what he's excited about—for this year's 2023 Controversies in Modern Eye Care meeting held this April in Los Angeles, California.

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

Flavio Mantelli, MD, PhD, Chief Medical Officer at Dompé, shares about the company's role in nerve growth factor (NGF) applications in ophthalmic disease and other human indications.

Protecting children’s eye health will demand a focus on vision and learning through better nutrition, myopia management, and disease prevention.